Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B
โ Scribed by Peter W. Angus; Geoffrey W. McCaughan; Edward J. Gane; Darryl H.G. Crawford; Hugh Harley
- Book ID
- 111722924
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 78 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1527-6465
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Patients undergoing liver transplantation for hepatitis B-related liver disease are prone to recurrence. The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (HBIG). Antiviral therapy with lamivudine has proven effective in lowering hepatitis B virus (HBV) DNA
Immunoprophylaxis using intravenous (IV) hepatitis B immune globulin (HBIG) decreases the recurrence of hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). However, IV HBIG is expensive, has significant side effects, and is inconvenient to administer. An alternative appro
Current protocols for prophylaxis against allograft reinfection after liver transplantation for chronic hepatitis B virus (HBV) infection include the administration of large doses of hepatitis B immune globulin (HBIG), with considerable associated economic costs. Monotherapeutic prophylaxis with lam